Summary
Since the outbreak of the novel corona virus disease 2019 (COVID-19) at the end of 2019, specific antiviral drugs have been lacking. A Chinese patent medicine Toujiequwen granules has been promoted in the treatment of COVID-19. The present study was designed to reveal the molecular mechanism of Toujiequwen granules against COVID-19. A network pharmacological method was applied to screen the main active ingredients of Toujiequwen granules. Network analysis of 149 active ingredients and 330 drug targets showed the most active ingredient interacting with many drug targets is quercetin. Drug targets most affected by the active ingredients were PTGS2, PTGS1, and DPP4. Drug target disease enrichment analysis showed drug targets were significantly enriched in cardiovascular diseases and digestive tract diseases. An “active ingredient-target-disease” network showed that 57 active ingredients from Toujiequwen granules interacted with 15 key targets of COVID-19. There were 53 ingredients that could act on DPP4, suggesting that DPP4 may become a potential new key target for the treatment of COVID-19. GO analysis results showed that key targets were mainly enriched in the cellular response to lipopolysaccharide, cytokine activity and other functions. KEGG analysis showed they were mainly concentrated in viral protein interaction with cytokine and cytokine receptors and endocrine resistance pathway. The evidence suggests that Toujiequwen granules might play an effective role by improving the symptoms of underlying diseases in patients with COVID-19 and multi-target interventions against multiple signaling pathways related to the pathogenesis of COVID-19.
Article PDF
Similar content being viewed by others
References
Rio CD, Malani PN. 2019 Novel Coronavirus-Important Information for Clinicians. JAMA, 2020,323(11):1039–1040
Wrapp D, Wang NS, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 2020,367(6483):1260–1263
Zumla A, Chan J, Azhar E, et al. Coronaviruses — drug discovery and therapeutic options. Nat Rev Drug Discov, 2016,15(5):327–347
Gao Y, Qiu HB, Zhou S, et al. Accumulated Clinical Experiences from Successful Treatment of 1377 Severe and Critically Ill COVID-19 Cases. Curr Med Sci, 2020, 40(4):597–601
Fu X, Lin L, Tan X. Clinical study on 37 case of COVID-19 treated with integrated traditional Chinese and Western Medicine. Zhongyao Xinyao yu Linchuang Yaoli (Chinese), 2020,31(5):600–604
Fu X, Lin L, Tan X. Clinical Study on Treatment of Cases of COVID-19 with Toujie Quwen Granules. Zhongguo Shiyan Fangjixue Zazhi (Chinese), 2020,26(12):44–48
Sohn EJ, Kim JM, Kang SH, et al. Restoring Effects of Natural Anti-Oxidant Quercetin on Cellular Senescent Human Dermal Fibroblasts. Am J Chinese Med, 2018, 46(4):853–873
Zhang D, Fang J, Chen J, et al. An in vitro study of antihuman cytomegalovirus effect of Forsythia suspensa and its main active ingredient quercetin. Zhongguo Zhongyao Zazhi (Chinese), 2010,35(8):1055–1059
Zhang ZM, Guo SJ, Fu SJ, et al. Research Progress of Active Ingredients and Pharmacological Action of Honeysuckle. Animal Husbandry Feed Sci, 2014(1):22–24
Sun Y, Xiong YY, Wu HZ, et al. Active Ingredients and Mechanism of Action of Rhizoma Coptidis against Type 2 Diabetes Based on Network-Pharmacology and Bioinformatics. Curr Med Sci, 2020,40(2):257–264
Xiong WC, Wu HZ, Xiong YY, et al. Network Pharmacology-based Research of Active Components of Albiziae Flos and Mechanisms of Its Antidepressant Effect. Curr Med Sci, 2020,40(1):123–129
Hopkins A. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol, 2008,4(11):682–690
Liu XK, Wu JR, Zhang D, et al. A Network Pharmacology Approach to Uncover the Multiple Mechanisms of Willd. on Colorectal Cancer. Evid Based Complement Alternat Med, 2018,2018:1–12
Liu J, Pei M, Zheng C, et al. A Systems-Pharmacology Analysis of Herbal Medicines Used in Health Improvement Treatment: Predicting Potential New Drugs and Targets. Evid Based Complement Alternat Med, 2013,2013(6):938764
Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res, 2003, 13(11):2498–2504
Xu Z, Shi L, Wang YJ, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med, 2020,8(4):420–422
Yu GC, Wang LG, Han YY, et al. clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters. Omics, 2012,16(5):284–287
Xu H. Research progress of prostaglandin receptors and related drugs. J China Pharm Univ, 2010,41(5):385–394
Mcdougall C, Mckay GA, Fisher M. Drugs for diabetes: Part 5 DPP-4 inhibitors. Br J Cardiol, 2011,18(3):130–132
Kitano, H. Systems Biology: A Brief Overview. Science, 2002,295(5560):1662–1664
Wang ZP, Xu XJ. scRNA-seq Profiling of Human Testes Reveals the Presence of ACE2 Receptor, a Target for SARS-CoV-2 Infection, in Spermatogonia, Leydig and Sertoli Cells. Cell, 2020,9(4):920
Xiao F, Tang MW, Zheng XB, et al. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology, 2020,158(6):1831–1833
Mao L, Jin HJ, Wang MD, et al. Neurologic Manifestations of Hospitalized Patients with Corona-virus Disease 2019 in Wuhan, China. JAMA Neurol, 2020,77(6):683–690
Zhi P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020,579(7798):270–273
Xu XT, Chen P, Wang JF, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci, 2020,63(3):457–460
Liu YX, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci, 2020,63(3):364–374
Author information
Authors and Affiliations
Corresponding authors
Additional information
Conflict of Interest Statement
The authors declare that they have no conflicts of interest.
The study was supported by the grants from the Education Department of Liaoning Province (No. LFW201701), Liaoning Provincial Key R & D Project (No. 2020JH2/10300114) and Key Laboratory of Shenyang Science and Technology Bureau (No.18-007-0-02).
Rights and permissions
About this article
Cite this article
Yang, By., Wang, Hz., Ma, Zz. et al. A Network Pharmacology Study to Uncover the Multiple Molecular Mechanism of the Chinese Patent Medicine Toujiequwen Granules in the Treatment of Corona Virus Disease 2019 (COVID-19). CURR MED SCI 41, 297–305 (2021). https://doi.org/10.1007/s11596-021-2346-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-021-2346-x